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Recent studies of timing of dialysis initiation have challenged
the recent trend to earlier initiation of therapy. The observed
outcomes though are a consequence of the balance between
the risks of advanced uremia versus the inherent dangers
relating to dialysis therapy itself. Many of these risks are
inherent in how dialysis treatment is currently carried out,
and may indeed be amenable to mitigation, through
refinement of clinical practice (and potentially modality
choice). This article aims to lay out a discussion relating to
patient outcomes being the composite result of this balance,
pivoting on the vulnerability of a particular patient to these
attendant risks.
Kidney International (2012) 82, 382–387; doi:10.1038/ki.2012.133;
published online 25 April 2012
KEYWORDS: complications of dialysis; hemodialysis; mortality; peritoneal
dialysis; residual renal function
Dialysis treatment has long been accepted as a life-saving
treatment in the setting of terminal uremia, and now offers
life-sustaining treatment to approximately two million people
around the world, in a wide variety of health-care systems.
Despite the widespread adoption of this life-saving therapy,
dialysis treatment (and in particular the initiation phase) is
redolent with dangers, many of which are only recently
starting to be fully appreciated. This inherent tension between
benefit and harm has, up to this point, been explored mainly
through a focus on timing of dialysis initiation. This area of
interest has been twinned with further consideration of
conservative nondialytic care in chronic kidney disease
(CKD) stage 5 patients; detailed discussion of this literature,
however, is beyond the scope of this particular article.
Conventional wisdoms have evolved concerning the
expected benefits of early dialysis initiation. These have largely
led to very similar national and international guidelines
regarding the best time to start dialytic treatment.1 These
guidelines have been associated with a marked increase over
the past decade in patients to commencing dialysis at an ever
earlier stage.2 The core question as to when the best time to
commence treatment, in both populations and individuals, has
received remarkably little systematic study. There has been only
a single randomized controlled trial examining the issue of
early- versus late-start dialysis initiation.3 The other investiga-
tions have almost entirely relied on retrospective interrogations
of registry or other observational data sets. These studies have
relied on statistical manipulations to adjust for case mix and
comorbidity burden. More recent iterations of this approach
have consistently identified earlier initiation as being associated
with poorer outcomes in both general populations and subsets
of younger patients without significant comorbidity.
Since 2001, 11 observational studies have examined the
issue of comorbidity-adjusted survival versus the estimated
glomerular filtration rate (eGFR) level (as assessed by the
serum creatinine-based Modification of Diet in Renal Disease
equation) at dialysis initiation. All but two of these studies
found a comorbidity-adjusted survival disadvantage of early
dialysis initiation, possibly underestimated by ‘lead time bias’,
and recently a variety of observational studies have reported a
graded survival benefit associated with lower eGFR.4–6
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Comorbidity has been considered a crucial factor in many
of the previous studies. LaSalle and co-workers7 found early-
start disadvantage only in patients with the highest level of
pre-dialysis comorbidity. Adjustment of survival for measured
comorbidity, however, still seems to suggest no advantage in
early start. However, comorbidity data collected at the registry
level has not been well validated, with only one published
study that found high specificity but low sensitivity of
comorbidity data from the US Renal Data System. Although
comorbidity is strongly associated with dialysis mortality,
one study of patients with a low comorbid burden has
also confirmed this trend to reduced survival in patients with
higher starting eGFR.4
The question of dialysis start has been the subject of a
recently published randomized controlled trial.3 Cooper and
colleagues3 randomly assigned 828 patients 18 years of age or
older to early dialysis start estimated GFR by surface area
corrected Cockcroft–Gault equation of 10–14ml/min or late
start estimated GFR of 5–7ml/min. During a follow-up period
of about 3.5 years, 152 of 404 patients in the early-start group
(37.6%) and 155 of 424 in the late-start group (36.6%) died
(hazard ratio with early initiation, 1.04; 95% confidence
interval, 0.83 to 1.30; P¼ 0.75). There was no significant
difference between the groups in the frequency of adverse
events (cardiovascular events, infections, or complications of
dialysis) or in quality-of-life measures. There appeared to be no
health economic benefit of an earlier start. However, it should
be noted that a significant proportion of patients randomized
to later start did in fact commence earlier, because of clinician
assessment of need (and indeed the majority commenced
peritoneal dialysis (PD), rather than hemodialysis (HD)).
These data are consistent with the proposition that exposure to
the harm associated with dialysis initiation overwhelms the
survival advantage related to attempted correction of uremia in
the setting of relatively less advanced CKD.
This article introduces the concept that outcomes in
dialysis are the composite result of negative effects of
advanced CKD, balanced by the attendant risks of dialysis
therapy, underpinned by the denominator of individual
vulnerability of the patient to both of the above. This
dynamic may be further influenced by attempts to mitigate
many of those risks.
POTENTIAL BENEFITS OF DIALYSIS INITIATION
Although advanced CKD is associated with a plethora of
metabolic, structural, and functional abnormalities, there is still
very little certainty in mapping the individual abnormalities to
specifics of patient symptoms or subsequent adverse events.
This has strengthened (by default) the focus on nutrition,
owing to the inability to robustly identify other surrogates for
outcome that might be manipulated by the dialysis process.
Malnutrition has been cited as the most common reason for
clinicians choosing an earlier start (other than absolutes such
as life-threatening hyperkalemia or oliguria-associated fluid
overload),8 and is contained in many guideline recommenda-
tions. This is largely driven by abundant observational data
identifying low serum albumin as being the strongest
determinant of mortality in dialysis patients. The NECOSAD
study group suggested that increasing small-solute clearance
(based on urea) might affect the observed pattern of
developing malnutrition after dialysis start.9 However, there
are currently no studies that directly support the ability of
conventional three-times-weekly dialysis to improve nutri-
tional parameters, especially without enhanced nutritional
supplements. No improvements were seen over 3 years of
follow-up in the HEMO study of prevalent HD patients in
either serum albumin or anthropomorphic measures of
nutrition.10 This study highlighted the importance of inflam-
mation and its associated effects on serum albumin (rather
than lower serum albumin being an exclusive or even primary
marker of malnutrition). In a recent study by Rosansky and co-
workers4, the increase in mortality risk propensity with earlier
dialysis initiation was preserved throughout the range of serum
albumin.
Advanced CKD leads to a wide variety of subjective
patient effects including pain, dyspnea, increasing fatigue,
dependency, and depression. There are no prospective studies
suggesting that initiation of current intermittent dialytic
therapies consistently address this symptom burden. The
application of more intensive dialysis regimes has been
associated with an increase in many measures of nutrition
and well-being.11 However, at present only a small fraction of
patients are undergoing this form of therapy, which is still at
the early stages of rigorous scientific assessment.
RISKS OF DIALYSIS
Conventional dialysis treatment has many inherent risks for
patients. This appears true in older frailer patients, and in
those with minimal comorbidity. Some of these risks are
fundamental to the dialytic therapy and some relate to
management of the patient during the period of transition
from nondialytic to dialytic management of end-stage renal
disease. These risks may potentially be mitigated.
The period of dialysis initiation is associated with a
particular increase in patient dependency (with similar
increment in mortality).12 In studies looking at longer-term
dialysis outcomes, the effects of these risks are not evenly
distributed over the entire dialysis vintage, with an excess of
mortality condensed into the first 6–12 months of therapy.4
Survival in the first year of dialysis (in the United States) has
decreased despite evidence of overall improvement in dialysis
patient survival overall.13 The window of opportunity for a
number of these risks is often in the dialysis preparation
period, with a reduced period for specialist care/preparation
being associated with increased mortality in the dialytic
phase of patient care.14
Specific areas of risks that must be considered when
initiating dialysis include the following:
Infection and dialysis access–related issues
Risks of all forms of infection are many times higher once
the patient is started on dialysis. This relates partially to
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uremic-induced immuno-incompetence, but also signifi-
cantly to vascular access in HD patients. Catheter-related
infections result either from migration of skin organisms
along the catheter into the bloodstream or contamination
and colonization of catheter lumens. Biofilm formation
(formed from a combination of host and bacterial molecules)
on the surface of catheters also has an important role in
facilitating colonization and resistance to antibiotic therapy.
Patients on dialysis are 100-fold more likely to develop
methicillin-resistant Staphylococcus aureus septicemia than
the general population and 800-fold more likely than if not
dialyzed with a native arteriovenous fistula.15 Exposure to
hospital-acquired infection is often just a component of the
myriad of dangers associated with the increased amount of
in-patient care, which is often characteristic. Others might
include exacerbation of malnutrition, hypostatic pneumonia,
falls, and venous thromboembolism risk.
Upper extremity native arteriovenous fistula is the
vascular access of choice, supported by the Dialysis Outcome
Quality Initiative (K/DOQI) of the National Kidney Founda-
tion. The use of definitive vascular access in HD patients,
rather than tunneled central venous catheters, is associated
with sustained reduction in mortality.16 This difference in
survival has previously been entirely attributed to differences
in access-related sepsis; however, it is being appreciated that
arteriovenous fistula formation is associated with a series of
structural and functional adaptations that reduce the
propensity to demand ischemia and result in a lower-risk
cardiovascular milieu (lower central blood pressure, reduced
arterial stiffness, and improved ventricular contractile func-
tion),17 and higher vascular access flows are associated with
reduced acute recurrent HD-related cardiac injury (myocar-
dial stunning).18
Decompensation of nutrition and psychosocial problems
The 6-month interval around the first dialytic treatment may
be one of mandated dietary restriction, depression, anxiety,
and reduced appetite. These changes result in patients being
exquisitely sensitive to worsening malnutrition. Patients
newly started on dialysis face the physical and time
requirements of their dialysis treatments (e.g., 4 h plus
travelling time, 3 days a week for HD, or fluid exchanges 4
times every day for PD). They are also required to adhere to
strict dietary restrictions and fluid restrictions despite having
to take a median of 19 tablets a day.19 Dialysis therapy and
underlying advanced CKD are associated with lethargy,
itching, pain dizziness on HD days, and bloating or
gastrointestinal disturbance while on PD.20 These factors
combine to sap patients’ confidence and interfere with
activity, exercise, and social engagement. Depression and
other psychosocial problems are often initiated or aggravated
by dialysis start, and are often associated with fundamental
reductions in a patient’s ability to socialize, or to remain in
chosen employment, amplifying these psychological stresses.
Clinical depression is highly prevalent, affecting around 25%
of patients,21 and correlates to mortality risk.
Specific dialysis-related risks
Cardiovascular effects. Current conventional HD is less
capable of exerting significant recurrent systemic circulatory
stress that may be important in the development of cardiac
disease, as well as perfusion-dependent injury of a wide range
of vulnerable vascular beds. These include gut, brain, and
potentially the kidney. This predominantly hemodynamic
injury can therefore result in a mixed picture of direct
perfusion-related injury, local/systemic inflammation, and
potentiation of further cycles of injury.22 Cardiac protection
(and potentially other organ systems as well) may be possible
by reducing this circulatory stress with modifications such as
daily dialysis therapies to limit ultrafiltration requirements.23
Cardiac arrhythmias and risk of sudden death appear to be
the most important final fatal consequence in HD patients. A
lengthening of the QT interval corrected for heart rate (QTc)
predisposes to torsade de pointes ventricular tachycardia, and
although many episodes may be self-terminating torsade can
degenerate into ventricular fibrillation. In non-uremic
patients, episodes of torsade de pointes often occur because
of a combination of factors, including a long QTc in
combination with bradycardia or electrolyte abnormalities
such as hypokalemia, hypomagnesemia, or hypocalcemia.
Several authors have reported an acute increase in both QTc
and QTd following dialysis. Although this would support the
increase in sudden death temporally related to the dialysis
procedure,24 there are relatively few data showing a direct
link between increased QTc or QTd induced by dialysis and
either arrhythmia or sudden death. Nakamura et al.25
compared two groups of 24 dialysis patients separated into
those who displayed an increase in QTc post dialysis and
those who did not. They reported an increase in cardiac
events and cardiac mortality in the group with an increase in
QTc post dialysis, but many of the outcomes were not
arrhythmias or sudden death.25 Conversely, two studies have
documented the increase in QTc with dialysis but found that
there was no resultant increase in arrhythmias.26,27
There is also a lack of consensus regarding the mechan-
isms underlying the acute increase in QTc and QTd with
dialysis. It would seem logical that shifts in plasma
electrolytes would be the main cause. In essence, the degree
of reduction and the absolute end-dialysis plasma concentra-
tions of potassium, calcium, magnesium, and pH have all
been linked to lengthening QTc and an increase in
arrhythmias, whereas other authors have not found such
associations. The longer interdialytic interval in three-times-
weekly dialysis schedules and the use of lower dialysate
potassium have been linked to increased risk of cardiac arrest
in HD patients.
Residual renal function. The maintenance of residual renal
function (RRF) is one of the key factors that has been
identified to associate with better survival in HD patients.28
An accelerated decline in RRF is, however, a characteristic
of initiation of conventional three-times-weekly dialysis.
This results in both a reduction in urine volume (with
exacerbation of long term fluid control and increased
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ultrafiltration requirements during each HD session) and a
reduction in the overall level of clearance of uremic toxins
(in particular middle molecule solutes). Previously we have
demonstrated that conventional HD has significant intradia-
lytic hemodynamic effects. We hypothesize that the renal
circulation is also vulnerable and that the same processes
may contribute to new recurrent renal ischemic injury,
driving the loss of RRF. This creates a vicious cycle with
falling RRF, resulting in increasing interdialytic fluid gains
and yet higher ultrafiltration requirements, driving
additional injury to vulnerable vascular beds. Dialysis-
associated loss of RRF is also associated with an increase in
sudden cardiac death.29
A detailed discussion of potential therapeutic approaches
to help preserve RRF is beyond the scope of this article but
might include the following: careful avoidance of dehydration
through diuretics or excessive ultrafiltration, consideration of
PD in preference to HD, and ensuring the use of only
biocompatible dialysis membranes and possibly PD fluids.
One potential approach to mitigate some of the risks
associated with dialysis initiation might be to adopt the
incremental approach, adding in additional HD time or
sessions, or even a planned early use of PD with transition to
HD, with subsequent waning of RRF. These approaches,
although apparently reasonable, have not been subjected to
rigorous study. Early use of even more intermittent short
HD runs risks of exacerbated circulatory stress, and
potential for further reduction in RRF. Tracking the
appropriate stepping up of delivered dialysis dose is also
challenging, especially at dialysis initiation with such
profound changes in body composition and cardiovascular
status. Additional use of PD also has inherent risks of the
complications of both therapies, both in terms of access and
cumulative metabolic stress. However, PD and HD have
been used in a combined approach30 in patients failing on
either initial solo modality or even de novo at the start of
renal replacement therapy.31
Peritoneal dialysis versus hemodialysis. Compared with
nondialysis patients, both HD and PD patients have an 8-fold
increase in cardiovascular risk and non-cardiovascular risks of
death. The pathophysiological mechanisms that result in this
high death rate are not well understood and may be different
in HD versus PD patients. In HD patients, cardiovascular
insults appear to be predominately hemodynamic and may
involve biocompatibility issues of dialyzers used. PD results in
hemodynamic effects, but the response associated with a low
ultrafiltration rate is not characteristically hypotensive and
does not result in acute cardiac injury.32 In both dialytic
modalities, the changes may be related to fluid type and
glucose exposure. Metabolic insults may drive cardiovascular
structural and functional pathophysiological processes.
Deposition of advanced glycation end products in vascular
tissues may result in reduced compliance of arteries and
ventricular muscle.33 Both short-term and longer-term
metabolic factors may alter autonomic reactivity. All of these
changes may prime patients to experience aberrant regional
blood flow to vital organ systems. This principally hemody-
namic versus metabolic comparison is superimposed on
differing patterns of infection between the modalities and
specific risks associated with peritoneal malfunction and
failure.
One potential approach to mitigate some of the risks
associated with dialysis initiation might be to adopt the
incremental approach, adding in additional HD time or
sessions, or even a planned early use of PD with transition to
HD, with subsequent waning of RRF. These approaches,
although apparently reasonable, have not been subjected to
rigorous study. Early use of even more intermittent short HD
runs risks of exacerbated circulatory stress, and potential for
further reduction in RRF. Tracking the appropriate stepping
up of delivered dialysis dose is also challenging, especially at
dialysis initiation with such profound changes in body
composition and cardiovascular status. Additional use of PD
also has inherent risks of the complications of both therapies,
both in terms of access and cumulative metabolic stress.
However, PD and HD have been used in a combined
approach in patients failing on either initial solo modality or
even de novo at the start of renal replacement therapy.
CONFLATION OF RISK AND SUSCEPTIBILITY: FUTURE
DIRECTIONS OF STUDY
Patients requiring dialysis are subject to significant functional
and structural abnormalities, which may sensitize them to
conventional mortality risks, as well as create other issues
that are unique to dialytic therapy. These drivers of mortality
may relate to end-stage CKD, dialytic therapy, and
an individual’s susceptibility to both (Figure 1 and Table 1).
To date, no attempt has been made to assess the relative
effects of all of these risks in a particular patient situation.
Research up to this point has focused on thresholds, failing to
embrace the reality of biology being essentially a continuum
Positive
effects of
relieving
advanced
uremia
Negative
consequences
of dialysis
initiation
Figure 1 |Chances of survival at any given starting glomerular
filtration rate are a complex dynamic balance between the
benefits of relieving advanced uremia and the risks of the
attendant therapy. The pivot point for this balance is the
individual patient tolerability of both the uremia and the
proposed renal replacement therapy. This pivot point itself is
somewhat different between patients and even within the same
patient over a period of time. The relative weight of the risk of
being markedly uremic may well be substantially less than those
inherent in dialysis (as it is commonly initiated and performed).
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(and therefore lacking biological plausibility). It also has been
predicated on there being more risk inherent in having
advanced uramia than that being faced associated with renal
replacement therapy.
Although such an approach might seem difficult, it is not
impossible. Risks from therapies can be quantified, such as
with the use of advanced real-time functional assessments
(tissue perfusion, systemic hemodynamic responses, cardiac
responses to dialysis treatment, and others), which can define
the response of a healthy human to a particular level of
dialytic stress.34 It may also be possible to focus on biological
factors that are acting as integrators of these susceptibilities.
Potential candidates might be humoral (markers of tissue
injury, inflammation, malnutrition, and others), whole-body
functioning (6-min walk test, sit to stand testing, and others),
health-related quality of life (with specific testing of disease-
related domains and so on), or body composition (measuring
hydration or reduction in lean body mass and so on). As an
example, muscle mass can be accurately assessed by measur-
ing muscle cross-sectional area (MCSA) on thigh CT. There
are many factors already reported as being associated on a
cross-sectional study basis with muscle wasting. These include
decreasing glomerular filtration rate, dialysis, age, and
diabetes.35,36 Muscle atrophy can be assessed by various
methods, and previous work has shown good correlation
between thigh MCSA and functional performance, serum
albumin, age, and inflammatory status in CKD stages 4–5,
HD, and PD patients. These changes have previously been
attributed to inadequate dietary protein intake, but recent
advances in our understanding of this area indicate that other
processes are involved. There is a prospectively observed
significant loss of muscle CSA in late-stage CKD 4, suggesting
that these patients are subject to increased disturbance of the
catabolic/anabolic balance, presumably as a result of advan-
cing uremia. This occurs at eGFRs between 10 and 20ml/
min.37 Dialysis initiation based purely on estimation of renal
function from serum creatinine runs the danger of allowing
patients to ‘loose ground’ in terms of overall nutritional status
in these late stages, and failing to optimally time dialysis
initiation. This raises the possibility that we might be able to
utilize this acceleration of muscle wasting as an individualized
biomarker of increasing metabolic decompensation, provid-
ing a rationale for when the appropriate time to start dialysis
in an individual might be.
An alternative approach might be to identify those patients
at particular risk of the cardiovascular effects of dialysis. An
approach based on the detection of large-vessel coronary artery
disease is unlikely to be useful, given the relatively reduced
significance of such findings in the dialysis population.
Appropriate cardiovascular stress studies, more sensitive
measures of reduced ventricular function (such as global
longitudinal strain), microcirculatory studies, or more ad-
vanced analyses of heart rate variability patterns (providing
information on autonomic function) all might hold promise.
The consequence, however, would potentially be to defer
dialysis initiation in those patients with documented patterns
of cardiovascular vulnerability. Application of such a strategy
might see our frailest and most vulnerable patients allowed to
Table 1 | Summary of the attendant recognized risks of dialysis
HD PD
Risks at initiation Increasing dietary restriction
Escalation of medication burden
Specific acute hospitalization risks Venous thromboembolism
Hospital-acquired infection
Dialysis access CRI Peritonitis
AVF/arteriovenous graft as portal of sepsis Exit site infection
Overall infection risk Pneumonia
Generalized increased bacteremia risk
Psychosocial Increasing dependency
Anxiety and depression
Dialysis specific Circulatory stress Acute and chronic metabolic stress
Cardiac injury
Brain ischemic injury
Increased bleeding risk
Inflammation Subclinical access infection
Biocompatibility issues
Translocation of endotoxin from gut due to congestion and
enteral ischemia
Sudden cardiac death Hemodynamic/ischemic stress of HD Loss of residual renal function
Electrolyte disturbance
Malnutrition Suppressed appetite Peritoneal protein losses
Disturbed catabolic/anabolic balance Appetite suppression by intra-abdominal
volume and hypertonic glucose fluids
Accelerated muscle wasting
Loss of residual renal function Biocompatibility Inappropriate low target weight and
inappropriate ultrafiltration
HD-related recurrent acute kidney injury
Abbreviations: AVF, arteriovenous fistula; CRI, catheter-related infection; HD, hemodialysis; PD, peritoneal dialysis.
HD and PD are considered separately to highlight that some of this risk profile is shared and some is far more dialysis modality specific.
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be exposed to worsening uremia, and worsened overall con-
dition when they did commence treatment. The risk/benefit
ratio for these patients (Figure 1) may be such that nondialytic
conservative management may be the wisest choice.
CONCLUSION
There is still considerable doubt concerning the optimal
timing of dialysis initiation. This is true for general popula-
tions, especially patient groups (elderly, diabetics) and indivi-
duals with unique susceptibilities to adverse outcomes with
dialysis initiation. Preliminary randomized controlled trial
and registry-based data have challenged conventional wisdom
that an earlier start is beneficial. To date, none of the studies
have considered the interaction between uremic need, dialysis-
related harm, and individual patient susceptibility to these
factors. This balance is very important, as currently we have
limited ability to establish the individual vulnerability to
either advancing CKD or dialysis initiation. The degree to
which the ‘pivot’ of this balance may be changed by addressing
elements of the patients’ particular vulnerability or the
weight of dialysis-associated risk is not yet fully understood.
Although direct testing of this central hypothesis (relating
to the balance of risk and vulnerability) is challenging,
consideration initially aimed at quantifying these individual
risks and integrating them to provide coherent choices for
initiation is a crucial priority to improve patient outcomes.
Such an enhanced appreciation of the biological realities
faced by our patients would allow the utilization of the
expensive and potentially harmful renal replacement resource
in the most effective manner.
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